Author: Editor

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms in Statistical Interpretation at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _______ Interview with Pavlos Msaouel here: https://www.oncologytube.com/video/do-we-still-need-the-p-value-mdandersonnews?channelName=kidneycancer

Javid J. Moslehi, M.D. Associate Professor of Medicine Director, Cardio-Oncology Program Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT) Vanderbilt University Medical Center Nashville, TN www.cardioonc.org Twitter: @CardioOncology discusses Immune-Related Cardiac Toxicities at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Bianca D. Santomasso MD, PhD Assistant Professor, Department of Neurology Memorial Sloan Kettering Cancer Center discusses Current Management Strategies for Immune Related Neurologic Toxicity at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Yinghong (Mimi) Wang, MD, PhD Director of Medication-Induced Colitis and Enteritis Director of Fecal Microbiota Transplantation Department of Gastroenterology, Hepatology and Nutrition at MD Anderson discusses Management of Immune Checkpoint Inhibitors Related GI Toxicity at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Raja-Elie E. Abdulnour, M.D. Assistant Professor of Medicine Pulmonary and Critical Care Medicine DFCI / BWH discusses Current Management Strategies for Immune Related Pneumonitis at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Kerry Reynolds, MD Clinical Director, Inpatient Oncology UnitsDirector, Severe Immunotherapy Complications ServiceMassachusetts General Hospital, Boston, MA discusses Establishing an Immune Related Adverse Event (iRAE) Service at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Fellowship Director, Society of Urologic Oncology Cardinal Bernardin Cancer Center Loyola University Health System discusses What is the optimal management of post-ablation recurrence? PRO SURVEILLANCE at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Raj Ayyagari M.D. Assistant Professor of Radiology Department of Radiology Yale University School of Medicine discusses What is Optimal for Management of Post-Ablation Recurrent RCC? at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson discusses the Optimal Management of Post-Ablation Recurrences PRO-Partial Nephrectomy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Rod J Ellis, M.D. FACRO Professor and Chair Radiation Oncology Penn State University Milton Hershey Medical Center Hershey Pennsylvania discusses RENAL SBRT – EVIDENCE, PATIENT SELECTION AND OUTCOMES at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Stenio de Cássio Zequi, MD, MSc, PhD Head of Referral Center for Urological Tumors Robotic and HIFU Programs at AC Camargo Cancer Center Livre-Docente Professor at São Paulo University/ Graduate School Antonio Prudente Foundation and Federal University of São Paulo LARCG – Latin American Renal Cancer Group- Founder and Coordinator discusses Management of the Complex Cystic Mass (Bosniak 3-4):Pro Surgical Treatment at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic Renal Mass: Gone Fishin’… for Minnows! at the 18th International Kidney Cancer Symposium 2019, Miami, FL. __________ Interview here: https://www.oncologytube.com/video/cystic-renal-masses-active-surveillance Interview here: https://www.oncologytube.com/video/cystic-renal-mass-treatment

William C Huang, MD Associate Professor and Vice Chair of Urology NYU School of Medicine Chief of Urology and Co-Director of Robotic Surgery Tisch Hospital / Perlmutter Cancer Center NYU Langone Health discusses Meaningful Endpoints for Surgical Trials for Localized RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological and Kidney Institute Cleveland Clinic discusses Meaningful Endpoints for a Surgical Trial for Localized RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL. ________ Interview with Steven Campbell here: https://www.oncologytube.com/video/surgical-trial-for-rcc-cleclinicmd

Sasan Setoodeh, MD Genitourinary Pathology Fellow University of Texas Southwestern, Dallas, Texas discusses the Effects of Immune Checkpoint Inhibitors on Morphology of Renal Cell Carcinoma at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Neil Mendhiratta MD, MS UCLA David Geffen School of Medicine discusses the Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry at the 18th International Kidney Cancer Symposium 2019, Miami, FL. Co-authors: Adebowale Adeniran MD1, Jamil Syed MD1, Tyler Valdez2, Dipti Sajed MD, PhD2, Peter Humphrey MD, PhD1, Sung-Hae Kang PhD2, Huihui Ye MD, MS2, and Brian Shuch MD2 1Yale New Haven Hospital, New Haven CT 2University of California Los Angeles, Los Angeles CA

Gennady Bratslavsky, M.D. Professor and Chairman Department of Urology Upstate Medical University Syracuse, NY discusses Surgical Insights For Variant Histology at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL. __________ Interview here: https://www.oncologytube.com/video/front-line-tki-based-treatment-for-non-clear-cell-rcc

Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis School of Medicine at the Kidney Cancer Association International Meeting, Miami FL November 15, 2019

Eric C. Kauffman, MD Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo NY Kidney Cancer Association Meeting, Miami FL November 15, 2019

Nizar M. Tannir, MD, FACP Ransom Horne, Jr. Professor for Cancer Research Professor and Chair ad interim Department of Genitourinary Medical Oncology discusses Renal Medullary Carcinoma: A Call to Action! at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Ying-Bei Chen, MD, PhD Associate Attending Pathologist Memorial Sloan Kettering Cancer Center discusses the Importance of Tumor Profiling for Rare Histology Variants at the 18th International Kidney Cancer Symposium 2019 in Miami, FL.

Michelle Hirsch, MD, PhD Associate Professor of Pathology Chief, Genitourinary Pathology Service Brigham and Women’s Hospital Harvard Medical School discusses the Updates in the WHO Kidney Cancer Classification Schemes at the 18th International Kidney Cancer Symposium 2019

Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved intratumoral concentrations that exceeded preclinical efficacy thresholds and induced intratumoral biomarkers of pharmacodynamic signaling and apoptosis indicating…

V.K. Gadi, MD of @SeattleCCA answers commonly asked questions of the AVIATOR study and shares how it will affect future treatment.

V.K. Gadi, MD of @SeattleCCA discusses the AVIATOR study for HER2-positive metastatic breast cancer. __________ Read here: https://www.seattlecca.org/clinical-trials/breast-cancer-nct03414658

Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse Events Management’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Axel Grothey discusses therapeutic sequencing and treatment approaches in colorectal cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse Events Management’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Scott Kopetz discusses novel agents and targets in colorectal cancer. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab discusses the optimal sequencing of current and emerging agents for the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-2 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. David H. Ilson provides an update on the current standard of care for gastric cancer in the first line setting. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Ghassan Abou-Alfa discusses novel agents and therapeutic targets for the treatment of biliary cancer. © 2019 Imedex, an HMP Company

Giorgio Scagliotti, MD @giorgioscaglio3 discusses the IASLC. _________ Read here: https://www.oncologytube.com/video/iaslc-open-comment-period-on-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer-resection-specimens-following-neoadjuvant-therapy-

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma and Light Chain (AL) Amyloidosis have been selected for six poster presentations to be featured at the American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10 in Orlando, Florida. Melflufen is a peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC). A wide range of clinical and preclinical data for melflufen in both multiple myeloma and AL amyloidosis will be presented at the ASH annual meeting. Two key data sets that will be…

Heidi Gray, MD @heidigraydrezn5 of @SeattleCCA @UWashOBGYN discusses the phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with ovarian or peritoneal cancer. _________ Read here: https://www.seattlecca.org/clinical-trials/gynecologic-cancer-nct02713386

-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study–Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity–Clinical trial collaboration with Merck announced to evaluate CDX-1140 with KEYTRUDA®- Celldex Therapeutics, Inc. (NASDAQ: CLDX) presented data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) information from the company’s ongoing CD40 agonist program. CD40 is an important target for immunotherapy, expressed on dendritic cells and other cells presenting antigen, as it plays a critical role in triggering innate and adaptive immune responses. CDX-1140 is a fully human agonist anti-CD40 monoclonal…

Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC. How will this affect clinicians and treatment today?

Richard Sainson, PhD @rcasainson of @kymabltd answers KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: how does this affect treatment?

Richard Sainson, PhD @rcasainson of @KymabLtd explains KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: what mechanism of action is the most relevant for targeting ICOS?

Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC.

Richard Sainson, PhD @rcasainson of @kymabltd shares Kymab’s new findings for KY1044 presented at the #CICON2019 annual meeting.

Ayman A. Saad, MD of @OSUCCC_James answers commonly asked questions regarding the @NCCN guidelines debut to manage complications and actually improve readiness for stem cell transplant recipients. _________ National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments. Today, the National Comprehensive Cancer Network® (NCCN®) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT), also known as stem cell transplant or historically as bone marrow transplant. This new resource provides step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards. This type of specialized treatment is increasingly…

– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming Medical Meeting – Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLAROâ„¢ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not…

Ayman A. Saad, MD of @OSUCCC_James discusses the @NCCN guidelines debut to manage complications and actually improve readiness for stem cell transplant recipients. ___________ National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments. Today, the National Comprehensive Cancer Network® (NCCN®) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT), also known as stem cell transplant or historically as bone marrow transplant. This new resource provides step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards. This type of specialized treatment is increasingly common, occurring approximately 22,000…

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax’s potent, highly selective oral Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.   “Dosing of the first patient in AUGMENT-101 represents an important milestone, both for the SNDX-5613 program and, importantly, for patients with genetically-defined acute leukemias, many of whom often do not achieve durable benefit from currently available treatment regimens,” said Briggs W. Morrison, M.D., Chief Executive Officer…

At the Icahn School of Medicine at Mount Sinai, the Human Immune Monitoring Center (HIMC) will use state-of – the-art high-throughput technology to test the therapeutic effects of Libtayo ® (cemiplimab-rwlc), a PD-1 antibody blockade developed by Regeneron Pharmaceuticals, Inc. and Sanofi. While immunotherapy has revolutionized the field of oncology, key issues remain — such as learning more about how these drugs work in human cancer— and many patients are still failing to respond to these therapies, leaving a need for a better understanding of how FDA-approved immunotherapies work and how we can use emerging therapies to further improve treatment…

— First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented at ASH – — Single dose of CD117-ADC demonstrates first-ever successful gene therapy transplant in primates without chemotherapy conditioning, in collaboration with NIH — — Additional presentations from across the pipeline will showcase progress in autoimmune diseases, blood cancers and genetic diseases –  Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients,…

Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic, castration-sensitive prostate cancer. How does this affect treatment and clinicians today? ______ Read here: https://ascopubs.org/doi/abs/10.1200/JCO.19.01701?journalCode=jco&

— MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients — Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. MAVIS is an adaptive phase III multicenter, double-blind, placebo-controlled trial to assess the safety and efficacy of seviprotimut-L, with primary endpoints of recurrence-free survival (RFS) and overall survival (OS) in patients with American Joint Cancer Committee (AJCC) Stage IIB / C, IIIA, IIIB / C melanoma at high risk of recurrence following definitive surgical resection. Highlights of the data presented include: Improved outcomes in Stage IIB/C patients: Interim analysis of subgroups suggested enhanced…

Address to Japan Society of Clinical Oncology focuseson opportunities to expand benefits to more patients Accomplished surgeon-scientist joined Roswell Park in 2016 Currently, immunotherapies work well for very few patients with breast cancer Dr. Takabe also speaking on how to support development of oncology leaders  Dr. Kazuaki Takabe, Roswell Park’s Chief of Breast Surgery, gave the keynote address at the annual meeting of the Japan Society of Clinical Oncology. BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center’s Chief of Breast Surgery, Kazuaki Takabe, MD, PhD, FACS, gave an Oct. 24 keynote address on immunotherapy for breast cancer at the 57th Annual Meeting of…